Pages
Team
Publications
- PHASE I DOSE-ESCALATION STUDY OF TIRAPAZAMINE CHEMOEMBOLIZATION FOR UNRESECTABLE EARLY- AND INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA
- Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma
- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Resources
- 2022 JVIR Editor’s Award Honoree / Distinguished Clinical Study, by the Journal of Vascular and Interventional Radiology (JVIR), the flagship journal of Society of Interventional Radiology (SIR)
- Converting Liver Tumors into Low-Oxygen Environment to Activate Drug to Drive Cell Death with Dr. Ray Lee Teclison
- Triggering a Systemic Immune Response Against Cancer
- World Cancer Research Day Highlights Innovation in Immuno-Oncology
- PHASE I DOSE-ESCALATION STUDY OF TIRAPAZAMINE CHEMOEMBOLIZATIONFOR UNRESECTABLE EARLY- AND INTERMEDIATE-STAGE HEPATOCELLULARCARCINOMA
- PharmaShots Interview: Teclison’s Ray Lee Shares Insights on the $5.9 Million Capital Raise
- Teclison raises $5.9M to advance solid tumor program
- Teclison Closes $5.9M Funding Round
- Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma
- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
